Press Release
11.04.2024
FORE Biotherapeutics presenting at Stifel 2024 Virtual Targeted Oncology Forum
Read more
Press Release
10.05.2024
FORE Biotherapeutics to Present at the 2024 RBC Capital Markets Global Healthcare Conference
Read more
Press Release
09.04.2024
FORE Biotherapeutics announces new nonclinical data highlighting the differentiation of plixorafenib in combination with MEK inhibition at #AACR24
Read more
Press Release
29.02.2024
FORE Biotherapeutics Names William R. Hinshaw as Chief Executive Officer
Read more
Press Release
01.02.2024
FORE Biotherapeutics to Participate in Upcoming Investor Conferences
Read more
Press Release
07.12.2023
FORE Biotherapeutics to Present at the 2023 RBC Capital Markets Private Company Conference
Read more
Press Release
17.11.2023
FORE Biotherapeutics Announces Oral Presentation at SNO 2023 Reporting Updated Phase 1/2a Results for Plixorafenib in BRAF V600 Advanced Solid Tumors, Including Novel Data for Patients with BRAF V600 Primary CNS Tumors
Read more
Press Release
10.11.2023
FORE Biotherapeutics Announces Oral Presentation of Phase 1/2a Plixorafenib Data at the Society for Neuro-Oncology 2023 Annual Meeting
Read more
Press Release
12.10.2023
FORE Biotherapeutics to Present Plixorafenib Nonclinical Data Highlighting Potential Differentiation at the 2023 AACR-NCI-EORTC International Conference
Read more
Press Release
23.08.2023
FORE Biotherapeutics Announces $75M in Series D Financing and CEO Transition
Read more